AbbVie obtained emraclidine, a potential novel M4-selective positive allosteric modulator (PAM), originally commercialised by ...

Scientists have pinpointed the binding site for low-dose ketamine on NMDA receptors, explaining its fast-acting effects on ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...

Nine-month Results Remain On Track for Net ProfitAd Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2024-Addex ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

The key difference between emraclidine and Cobenfy is that emraclidine is a selective allosteric M4 agonist which means it ...

Beijing Primegene Therapeutics Co. Ltd. has patented macrocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) allosteric inhibitors reported to be useful for the ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

Using analysis from an open-label, long-term treatment study of the RNS ® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal ...